NCT02035215View on ClinicalTrials.gov

Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia

PHASE3UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions
Hyperlipidemia, Familial Combined
Interventions
DRUG

Atorvastatin 20mg

DRUG

Omega-3-acids ethylesters 90 4g

OTHER

Placebo(Omega-3-acids ethylesters 90)

Trial Locations (4)

431-070

ACTIVE_NOT_RECRUITING

Hallym University Sacred Heart Hospital, Anyang, Gyeonggi

405-760

NOT_YET_RECRUITING

Gachon University Gil Hospital, Incheon

152-703

RECRUITING

Korea University Guro Hospital, Seoul

480-717

ACTIVE_NOT_RECRUITING

Uijongbu St. Mary's Hospital, Uijongbu, Gyeonggi

Sponsors
All Listed Sponsors
lead

Kuhnil Pharmaceutical Co., Ltd.

INDUSTRY

NCT02035215 - Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia | Biotech Hunter | Biotech Hunter